Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results

(2017) S. J. Schuster et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vitro Expansion Improves In Vivo Regulation by CD4+CD25+ Regulatory T Cells

(2014) J.-G. Chai et al.   JOURNAL OF IMMUNOLOGY

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

(2009) Ravi A Madan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis

(2009) B. B. Ganesh et al.   INTERNATIONAL IMMUNOLOGY

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

(2008) Celestia S. Higano et al.   CANCER

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

(2008) C. T. Garnett et al.   CLINICAL CANCER RESEARCH

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy

(2008) R. A. Madan et al.   CLINICAL CANCER RESEARCH

Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer

(2007) Punam H Patel et al.   ANNALS OF PHARMACOTHERAPY

Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer

(2004) J.D. Eaton et al.   BJU INTERNATIONAL